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Humanleukocyteantigen(HLA)-Eisanonclassicalmajorhistocompatibilitycomplex(MHC)classImoleculeoflimitedsequence
variability that is expressed by most tissues albeit at low levels. HLA-E has been ﬁrst described as the ligand of CD94/NKG2
receptors expressed mainly by natural killer (NK) cells, thus conﬁning its role to the regulation of NK-cell function. However,
recent evidences obtained by our and other groups indicate that HLA-E complexed with peptides can interact with αβ T-cell
receptor (TCR) expressed on CD8+ T cells. Although, HLA-E displays a selective preference for nonameric peptides, derived from
the leader sequence of various HLA class I alleles, several reports indicate that it can present also “noncanonical” peptides derived
from both stress-related and pathogen-associated proteins. Because HLA-E displays binding speciﬁcity for innate CD94/NKG2
receptors, as well as all the features of an antigen-presenting molecule, its role in both natural and acquired immune responses has
recently been re-evaluated.
1.Introduction
Major histocompatibility complex (MHC) class I molecules
may be subdivided into two families, MHC class Ia (clas-
sical) and MHC class Ib (nonclassical). Both classical and
nonclassical MHC class I molecules are expressed at the cell
surface in association with β2-microglobulin. MHC class Ia
molecules (human leukocyte antigen (HLA)-A, -B, and -C,
in humans) [1] play a central role in adaptive immunity.
They interact directly with T-cell receptors (TCRs) and with
the coreceptor molecule CD8 on cytotoxic T cells (CTLs). In
humans, the MHC class Ib family members include HLA-
E, -F, -G, and HFE (HLA-H) [2]. They are best known
for their capability of regulating innate immune responses.
Nevertheless, there is now accumulating evidence that, like
the MHC class Ia molecules, certain class Ib molecules can
play a role also in regulating acquired immune responses
to bacteria and viruses [2, 3]. While, classical MHC class
I molecules are extremely polymorphic, nonclassical MHC
class I molecules are poorly polymorphic and, in most
instances, exhibit a narrow tissue distribution. In addition,
cellsurfaceexpressionofMHCclassIbmoleculesisgenerally
lower than that of MHC class Ia molecules. In humans,
HLA-E is the least polymorphic of all the MHC class I
molecules [4]. Several studies reported that only two alleles
predominate in the Caucasian population. These two alleles
HLA-E∗0101 (HLA-E107R) and HLA-E∗0103 (HLA-E107G)
diﬀer at only one amino acid position. Thus, an arginine
at position 107 in HLA-E∗0101 (HLA-E107R) is replaced
by a glycine in HLA-E∗0103 (HLA-E107G). In most cases
the HLA-E107G allele is expressed at signiﬁcantly higher
levels than the HLA-E107R allele on normal cells [5]. The
diﬀerences in surface expression of the two alleles do not
reﬂect only the higher aﬃnity of HLA-E107G for available2 Journal of Biomedicine and Biotechnology
peptides, but also the higher stability of surface HLA-
E107G/peptide complexes. HLA-E displays a relatively high
degree of peptide binding ability [6]. Under physiological
conditions, cell surface expression of HLA-E depends on
binding of nonamer peptides derived from the signal
sequence of MHC class I molecules [7]. The assembly of
HLA-E with the signal peptide-derived ligands is strictly
dependent on a functioning processing machinery (i.e.,
proteasome and the transporter associated with antigen
processing, TAP) [7, 8]. Unlike the other MHC class Ib
molecules, HLA-E is transcribed virtually in all human
tissuesandcelllines,althoughatlowerlevelsthanMHCclass
Ia antigens [9, 10]. Recently, unusually high levels of HLA-
E have been detected in neoplastic cells [11, 12]. Although,
HLA-E was ﬁrst described as the ligand for CD94/NKG2A
(inhibitory) and CD94/NKG2C (activating) NK receptors
[13–15], thus mainly conﬁning its regulatory function to NK
cell population, emerging evidence (obtained by our and
other groups) clearly support the notion that HLA-E can
serve as a restricting element for the TCR of some αβ Tc e l l s
[16–20]. Along this line, this MHC class Ib molecule plays
an important role in both natural and acquired immune
responses [21].
2.HLA-EDoes Bind DifferentSets of Peptides
As indicated above, HLA-E is a conserved class Ib molecule
characterized by a limited polymorphism. It binds non-
americ leader peptides primarily derived from amino-acid
residues 3–11 of the signal sequences of most HLA-A, -B,
-C and -G molecules (e.g., VMAPRTLIL, VMAPRTLVL,
VMAPRTLLL, VMAPRALLL, and VMAPRTLFL) [7]. Pep-
tide binding stabilizes the HLA-E protein, allowing it to
migrate to the cell surface. A functioning TAP molecule
is required to transport these peptides into the endoplas-
mic reticulum (ER), where they can interact with HLA-E
[7]. Although, HLA-E appears to bind a narrow peptide
repertoire, recent evidences revealed that several proteins
other than MHC class I molecules encode peptides that can
bind to HLA-E. Among these peptides the best character-
ized are the VMAPRTLVL and the VMAPRTLIL peptides
derived from the gpUL40 leader sequences (gpUL4015-23)
of two diﬀerent human cytomegalovirus (CMV) strains
(i.e., Toledo and AD169 strains). These peptides match
exactly the leader sequence peptides of various HLA-A
and -Cw alleles, respectively. Importantly, unlike the MHC-
derived peptides, the gpUL40-derived ones are assembled
with HLA-E via a TAP-independent mechanism [22]. In
addition, peptides derived from the human heat shock
protein60(hsp6010-18,QMRPVSRVL)[23],theATP-binding
cassette transporter, multidrug resistance-associated protein
7( M R P 7 496-504,A L A L V R M L I )[ 24], the human immunode-
ﬁciencyvirus(HIV)gagprotein(HIVp2414-22,AISPRTLNA)
[25], the Salmonella enterica serovar Typhi GroEL protein
(GroEL15-23, KMLRGVNVL) [20], and gliadin (gliadin α2
chain52-60, SQQPYLQLQ) [26] have also been shown to bind
HLA-E.
Interestingly, binding to HLA-E has been demonstrated
also for viral peptides previously shown to bind classical
HLA class I molecules. For example, peptides from the
Epstein-Barr virus (EBV) BZLF-1 protein (BZLF-139-47,
SQAPLPCVL), the inﬂuenza matrix protein (InﬂM59-67,
ILGFVFTLT) [27], and the Hepatitis C virus (HCV) core
protein (HCV Core35-44, YLLPRRGPRL) [28]a r ev i r a lp e p -
tides capable of binding to both HLA-A2 and HLA-E. Along
this line, we have recently demonstrated that also peptides
encoded by cellular-associated proteins can display a dual
binding speciﬁcity (namely, they bind to both HLA-A2 and
HLA-E). Thus, two alternative splicing isoforms of mutant
peroxiredoxin 5 (Prdx5) encode two nonapeptides (Prdx5
splicevariant(Prdx5Δ2)52-60,AMAPIKTHLandPrdx5splice
variant(Prdx5Δ2,3)52-60,AMAPIKVRL)abletobindtoboth
HLA-A2andHLA-Eandtoallowtheircellsurfaceexpression
[29]. It is of note that the amino acid sequences of some
of these HLA-E-binding peptides (derived from pathogen-
associated, stress-related or normal proteins) diﬀer markedly
in sequence from the canonical MHC class I-derived leader
sequence peptides.
3 .HLA - EI sR ec ogniz edb yTC ell svia
theirαβ TCR
CD8+ CTLs expressing αβ TCR generally recognize antigen
peptides in association with MHC class Ia molecules [30].
MHC class Ia molecules are central to allow CTL-mediated
discrimination between self and nonself. Thus, they present
antigens, in the form of 8–10 amino acid-long peptides, to
the αβ TCR expressed by CD8+ T cells. HLA class Ia-αβ
TCR interactions induce T lymphocytes to kill cells that are
infected by viruses or some intracellular bacteria. MHC class
Ia peptide epitopes, in most instances, are generated from
the proteasomal degradation of cytosolic proteins and their
loading into MHC class Ia is dependent on TAP function.
The ability of MHC class Ib molecules to stimulate T-cell
responsesemergedonlyinrecentyears.Variousexperimental
evidences revealed that MHC class Ib molecules may be
recognized by T cells. Thus, while it is well established
that HLA-E plays an important role in innate immunity,
functioning as ligand for the CD94/NKG2 killer lectin-like
receptors [13, 31] expressed by most NK cells [32]a n da
subset of CTLs [33–35], it is now clear that it can present
peptide antigens for αβ TCR-mediated recognition [16–
20, 36]. Several studies have characterized HLA-E-restricted
T cells. HLA-E dependent presentation of bacteria-derived
antigens to human CD8+T-cells has been documented. In
particular, bacteria, including Mycobacterium tuberculosis
(Mtb) and Salmonella enterica serovar Typhi GroEL, can
elicit HLA-E-restricted T-cell responses [19, 20]. In addi-
tion, our group has recently demonstrated that an HLA-
E-restricted CD8+ T cell subset represents a signiﬁcant
component of the adaptive immune response to CMV in
genetically predisposed individuals [36, 37]. Recently, other
authors demonstrated that chronic hepatitis C is associated
with increased intrahepatic HLA-E expression and showed
that HCV gives rise to a peptide that binds to HLA-E
and can be recognized by CD8+ T cells via their TCR
[38].Journal of Biomedicine and Biotechnology 3
4. Role of HLA-E-Restricted
CD8
+ T Cells inInfections
4.1. Nonclassically Restricted CD8+ T Cells in the Host
ResponsetoMtb. Mtbrepresentsaleadingcauseofinfectious
disease morbidity and mortality worldwide. In addition to
CD4+ T-cells, also CD8+ T lymphocytes appear essential for
the containment of mycobacterial infection. The importance
of HLA-E-restricted T cells in the host response to infection
with Mtb has been deﬁned by Heinzel and coworkers
[19]. In particular, they found that these cells comprise
the dominant CD8+ T cell response in latently infected
individuals. Remarkably, this ﬁnding represents the ﬁrst
compelling evidence of the ability of HLA-E to present
pathogen-derived antigens and extended the function of
HLA-E beyond its well-known role as an NK inhibitor
throughtheinteractionwiththeCD94/NKG2Aheterodimer.
Although, the recognized Mtb-derived peptides have not
been identiﬁed so far, Mtb-derived antigen presentation
was found to require proteasomal processing, but not TAP-
mediated peptide transport.
4.2. HLA-E Restricted CD8+ T Cells in the Host Response to
HCV Infection. HCV is a single-stranded RNA virus belong-
ing to the ﬂaviviridiae family. HCV infection is a common
cause of liver disease worldwide. In most instances, HCV is
not eliminated by the host and results in chronic infection,
which may develop into cirrhosis and hepatocarcinoma. The
mechanisms favoring persistent infection are still poorly
understood. However, numerous studies clearly indicate an
association between an impaired immune response and clin-
icaloutcome.PatientswhospontaneouslyrecoverfromHCV
infection typically mount vigorous multi-epitope-speciﬁc
CD4+ and CD8+ T-cell responses that are readily detectable
in blood samples.Bycontrast,patients withchronic hepatitis
C tend to have late, transient and narrowly focused T-cell
responses [39]. Recently, some authors suggested an impor-
tant role for HLA-E in regulating antiviral immunity. With
respect to HCV infection they demonstrated that chronic
hepatitis C is associated with enhanced intrahepatic HLA-E
expression [25]. In particular, they showed that HCV gives
rise to the YLLPRRGPRL peptide (HCV core amino acid 35-
44) that binds to, stabilizes HLA-E surface expression and
protects cells from the NK cell-mediated cytotoxicity [25].
More importantly, they showed that, beyond its interaction
with the CD94/NKG2A receptor, peptide-loaded HLA-E
molecules can also be recognized by CD8+ T-cells via their
TCR [38]. Patients with chronic HCV infection were ana-
lyzed for their nonclassical CD8+ T cell responses by using
HLA-E transfected K562 cells, loaded with the appropriate
HCV peptide, as antigen-presenting cells in an interferon
(IFN)-γ ELISPOT assay. Interestingly, by this approach, they
found that in nearly half of the HCV patients analyzed an
HLA-E-restricted HCV-speciﬁc CD8+ T-cell response could
be detected. It is of note, that HLA-E –restricted IFN-γ
secretion was associated with low viral load. Importantly,
no IFN-γ production was found in CD8+ Tl y m p h o c y t e s
from healthy controls, conﬁrming the speciﬁcity of this
ﬁnding. Finally, they provided the ﬁrst evidence for diﬀerent
functional roles of the 2 conﬁrmed HLA-E allelic variants
(i.e., HLA-E107R and HLA-E107G) in hepatitis C infection.
Thus, when patients were stratiﬁed according to HLA-E
genotype, they found that the frequency of HLA-E-restricted
responses was higher in patients homozygous for the HLA-
E107R alleleascomparedtocarriersofotherHLA-Egenotypes
[38].
4.3. HLA-E-Restricted CD8+ T Cells in the Host Response
to CMV Infection. Human CMV is a β-herpesvirus that
largely infects the human population, resulting in life long
persistent asymptomatic infection, which, however, may
causeseveremorbidityinimmunocompromisedindividuals.
CMV infection is the most common viral complication
following allogeneic hematopoietic stem cell transplantation
and solid organ transplantation. Speciﬁc cytotoxic T-cell
immunity represents a key factor to cointain CMV. Human
CMVhasevolvedanimpressivevarietyofstrategiestoescape
from the recognition mediated by conventional (i.e., MHC
class Ia-restricted) CTLs. Diﬀerent CMV viral proteins (i.e.,
the unique short, US, proteins) are well known to inhibit the
MHC class I expression in infected cells. In particular, the
human CMV gene products US2 and US11 bind to nascent
HLA class I chains resulting in their shuttle from the ER
to the cytosol, where they undergo proteasome-dependent
degradation. US3 binds to HLA class I molecules and retains
them in the ER. Finally, the TAP-mediated transport of
antigenic peptides to the ER is blocked by US6 [40]. As
a consequence, conventional HLA class Ia-restricted CTLs
may result, at least in part, ineﬃcient in counteracting CMV
infection. Interestingly, human CMV increases the surface
expression of HLA-E, while downregulating the expression
of many other MHC class I molecules [41]. Thus, human
CMV itself, through the expression of gpUL40 protein, can
supply peptides, which bind HLA-E in a TAP-independent
fashion. This results in surface expression of HLA-E at even
higher concentrations than in uninfected cells [22, 41, 42].
Notably, the upregulation of HLA-E in CMV-infected cells
hasbeen interpreted asa mechanism of viral escapefromNK
cells expressing the inhibitory CD94/NKG2A receptor.
Studies performed in our lab provided evidence that
some CD8+ T cells (via their TCR) recognize HLA-E when
loaded with peptides (i.e., VMAPRTLIL and VMAPRTLVL)
derived either from the gpUL40 proteins of diﬀerent human
CMV strains (e.g., AD169 and Toledo) or from the leader
sequences of various classical HLA class I alleles [36]. In
addition, we also obtained direct evidence in vitro that HLA-
E-restricted CD8+ T-cells can recognize and kill ﬁbroblasts
infected with human CMV strain AD169 [37]. These ﬁnding
may have particular relevance in the immune defenses
against CMV. Thus, HLA-E-restricted CD8+ T cells could
represent an additional type of eﬀector cells playing a role
in defense against a virus which can escape recognition
mediated both by CTLs restricted by classical HLA class I
molecules and by NK cells. Indeed, HLA-E-restricted CD8+
T cells are able to kill infected cells despite the sharp
downregulation of HLA class Ia, by recognizing the gpUL40-
derived VMAPRTLIL peptide presented in the context of
HLA-E [37].4 Journal of Biomedicine and Biotechnology
It is of note that, diﬀerent CMV strains have a mutated
form of gpUL40 from which diﬀerent HLA-E-binding
peptides can be generated [22, 43]. For example, the open
reading frame UL40 encoded by the CMV Toledo strain
contains the sequence VMAPRTLVL in its predicted leader
peptide. This nonamer is identical to the HLA-E-binding
peptidepresentinthesignalsequenceoftheHLA-A∗02allele
[22].Inagreementwiththeseﬁndings,alsoHLA-E-restricted
CD8+ TcellsspeciﬁcfortheVMAPRTLVLpeptidehavebeen
identiﬁed [36].
Donors that are able to develop an anti-CMV HLA-
E-restricted CD8+ T-cell response can be divided into
two diﬀerent groups according to their HLA-A and HLA-
Cw haplotype (Table 1). In particular, “group 2” donors,
from which HLA-E-restricted CD8+ T cells speciﬁc for the
VMAPRTLIL peptide could be derived, are characterized by
a particular HLA class I haplotype that does not contain
any VMAPRTLIL-bearing HLA-Cw alleles [36]. Thus, in
these individuals this peptide represents a foreign antigen.
On the other hand, donors who express HLA-Cw alleles
carrying the VMAPRTLIL peptide, fail to generate HLA-E-
restricted CD8+ T cells speciﬁc for this self-peptide Thus,
in these donors, HLA-E-restricted CD8+ Tc e l lp r e c u r s o r s
may have been negatively selected in the thymus by HLA-
E/VMAPRTLIL self-complexes. Along this line, “group 1”
donors, from which HLA-E-restricted CD8+ T cells speciﬁc
for both VMAPRTLIL and VMAPRTLVL peptides could be
derived, do express in their haplotype neither VMAPRTLIL-
bearing HLA-Cw alleles nor VMAPRTLVL-bearing HLA-A
alleles [36]. Thus, these peptides represent foreign antigens
for these donors. In summary, VMAPRTLIL represents
a nonself peptide for “group 1” and “group 2” donors,
and it is recognized with high avidity by HLA-E-restricted
CD8+ T cells from both groups. On the other hand,
VMAPRTLVLrepresents aself-peptide for“group2”donors,
and is therefore recognized only by “group 1” donors.
Taken together, these data suggest that the HLA class I host
genotype, as well as the infecting CMV strain, may deeply
aﬀect the ability of diﬀerent individuals to exploit HLA-
E-restricted CD8+ T cell-mediated defenses against CMV
infection. Along this line, it is possible to speculate that
only individuals carrying a particular MHC class I haplotype
thatlackstheVMAPRTLILpeptide(i.e.,HLA-Cw∗02and/or
HLA-Cw∗07) are more resistant to severe CMV infection
and/or reactivation occurring under certain pathological
conditions. Because CMV UL40-derived VMAPRTLIL and
VMAPRTLVL peptides are identical to those derived from
the leader sequences of various HLA class I alleles, HLA-
E-restricted CTLs may display a broad cytolytic activity
againstvariousHLA-E+ allogeneictumorcelllinesbelonging
to diﬀerent histotypes (a function referred to as NK-like
activity) [33]. In addition, these eﬀectors cells are charac-
terized by the surface expression of HLA class I-speciﬁc
inhibitory NK receptors (iNKRs) (i.e., KIR, CD94/NKG2A
and ILT2/LIR1) [44, 45] and by mono-, oligoclonal TCR Vβ
rearrangements, diﬀerent in diﬀerent donors [34]. Finally,
by the use of HLA-E tetramers refolded with diﬀerent
peptides we also provided evidence that these cells are
present in vivo, where they represent a sizeable fraction
of CD8β+T cells in some CMV seropositive individuals.
These cells display an eﬀector-memory surface phenotype
(CD27−CD28−CD45RA+CCR7−) and express intracellular
cytotoxic granules containing perforin and granzymes. In
addition, functional analysis revealed that HLA-E-restricted
CD8+ T cells are capable of prompt production of IFN-
γ upon speciﬁc peptide stimulation [37]. All the various
phenotypic and functional data illustrated above, together
with the fact that HLA-E-restricted CD8+ T cells represent
a oligo-, monoclonal expansion characterized by the expres-
sion of HLA class I-speciﬁc iNKRs, support the notion that
they are eﬀector-memory T cells possibly resulting from a
chronic, antigen-driven stimulation [46] .T h ep r e s e n c eo f
these eﬀector cells in the CD8+ T-cell memory pool of some
CMVseropositive individuals, strongly suggeststhat HLA-E-
restricted CD8+ T cells may actually play a relevant defensive
role during CMV infection.
5. Possible Role of HLA-E-RestrictedCD8
+
TCellsinImmune Responses againstTumors
HLA-E expression by tumor cells has been recently reported
in several types of human cancers. Notably, HLA-E may be
overexpressed in fresh lymphomas [47], ovarian carcinomas
[48], gliomas [49], colon cancer [50], and melanomas
[12]. Because of its capacity to bind to the inhibitory
CD94/NKG2A receptor expressed by NK cells and a subset
of T cells, HLA-E expression by neoplastic cells might
favor tumor cell escape from immunosurveillance. Thus,
it has been reported that NK cell activity against glioma
cell cultures could be greatly increased when HLA-E was
downregulated by RNA interference [49]. To date, the
potential role of HLA-E as antigen-presenting molecule for
tumor-speciﬁc CD8+ T cells has been poorly addressed and
tumor-derived peptides with binding speciﬁcity for HLA-E
have not yet been identiﬁed. However, we recently showed
that peptides speciﬁc for both HLA-E and classical HLA class
I molecules (i.e., HLA-A2) could be generated by alternative
splicing of the peroxiredoxin 5 (Prdx5) gene [29]. Prdx5
splice isoforms show widespread expression in normal and
neoplastic cell lines belonging to diﬀerent histotypes. As a
result of the splicing events, Prdx5 isoforms encode two
distinct nonapeptides (AMAPIKTHL or AMAPIKVRL) that
bind to HLA-A2 and HLA-E molecules, stabilize HLA-A2
and HLA-E and allow their cell surface expression. Interest-
ingly, we recently found that HLA-E+ targets, loaded with
these peptides, are recognized (although with low avidity),
by HLA-E-restricted CD8+ CTLs generated from healthy
donors [29]. On the other hand, complexes composed by
HLA-E and Prdx5 splice peptides are not recognized by
the CD94/NKG2A inhibitory receptor and thus do not
downregulate the NK cell function. Increased levels of Prdx5
can be detected in several diseases, such as osteoarthritis
and tendon degeneration [51, 52]. Its upregulation has
been reported during acute inﬂammation induced in rat
lung by LPS, in chondrocytes by IL-1α and TNF-α and in
human tendon cells during H2O2 exposure. In melanoma
cells, Prdx5 expression can be upregulated by diﬀerentJournal of Biomedicine and Biotechnology 5
Table 1: Both the HLA class I host haplotype and the infecting CMV strain can aﬀect the ability of diﬀerent individuals to exploit an
HLA-E-restricted CD8+ T-cell-mediated defence against CMV.
Donors HLA-Cw haplotype HLA-A haplotype VMAPRTLIL
1 VMAPRTLVL
2 HLA-E restricted CD8+ T
cells against CMV
Group 1
HLA-Cw∗02, -Cw∗07,
-Cw∗0809, -Cw∗15,
-Cw∗1701, Cw∗1703, and
-Cw∗183
HLA-A∗01, -A∗03, -A∗11,
-A∗29, -A∗30, -A∗33,
-A∗3401, -A∗36, -A∗74,
and -A∗804
nonself peptide nonself peptide YES (against both AD169
and Toledo strains)
Group 2
HLA-Cw∗02, -Cw∗07,
-Cw∗0809, -Cw∗15,
-Cw∗1701, Cw∗1703, and
-Cw∗183
HLA-A∗02, -A∗23, -A∗24,
-A∗25, -A∗26, -A∗3402,
-A∗43, -A∗66, and -A∗695
nonself peptide self peptide
YES (against AD169 strain
but not against Toledo
strain)
1This peptide is contained in the UL40 open reading frame (ORF) from human CMV AD169 strain.
2This peptide is contained in the UL40 ORF from human CMV Toledo strain.
3These HLA-∗CW alleles do not contain in their leader sequences the VMAPRTLIL peptide.
4These HLA-∗Aa l l e l e sdo not contain in their leader sequences the VMAPRTLVL peptide.
5These HLA-∗Aa l l e l e sdo contain in their leader sequences the VMAPRTLVL peptide.
forms of cellular stress. Along this line, HLA-E-binding
peptides such as those derived from alternatively spliced
Prdx5 isoforms, may be induced under stress conditions and
could contribute to HLA-E stabilization leading to CD8+-
mediated recognition of tumor cells. It is therefore possible
that when endogenous and environmental oxidative stress
levels alter normal cellular processes and induce cell damage,
as it might occur in cancer, peptides derived from Prdx5
variants may provide a signal that could activate MHC class
Ib-restricted T cells, thus contributing to the elimination of
stressed cells.
6. Concluding Remarks
While, the T-cell recognition of murine MHC class Ib
molecules was described over a decade ago, the ability of
human HLA class Ib molecules to stimulate T-cell responses
is only now being recognized. Nevertheless, it is still unclear
whether HLA-F and -G are involved in stimulating CD8+
T cells. HLA-G-restricted T cells that speciﬁcally recognize
pp65-derived peptides and kill HCMV-infected astrocytoma
cells, have been generated in transgenic mice [3]. However,
further studies are needed to evaluate how and whether such
induction of the HLA-G-restricted, anti-HCMV response
exists in humans. In addition, although it has been reported
that HLA-H (HFE) can be directly recognized by the αβ TCR
of CD8+ T - c e l l si nat r a n s g e n i cm o u s em o d e l ,i ti su s u a l l y
unable to present antigenic peptides [53].
Conversely, during the past years a series of relevant
discoveries unraveled several important functions of the
poorly known MHC class Ib molecule HLA-E in humans.
After the original report that HLA-E represents the ligand of
CD94/NKG2 receptors, which are expressed by NK cells and
CD8+ T cells, it became evident that HLA-E can represent a
restrictionelementforsomeTcellscharacterizedbycytolytic
activity [17]. In most instances, they appear to represent
oligoclonal or even monoclonal cell expansions. A relevant
work pointed out how these cells may kill a number of
allogeneic normal or tumor cells (the so-called NK-like
activity) upon recognition of HLA-E/peptide complexes on
target cells [17]. This problem may represent a serious
threat in transplantation [54, 55]. More recently, a number
of studies revealed that HLA-E-restricted CTLs recognize a
number of HLA-E-binding, pathogen-derived peptides, thus
revealingthelikelyroleexertedbythesecellsinhostdefenses.
Remarkably, in certain viral infections (CMV and, possibly,
HCV infections), HLA-E-restricted CTLs may play a role
complementary to that of conventional (i.e., HLA class Ia-
restricted) CTLs [37, 38, 56]. In particular, in human CMV
infection, downregulation of HLA class Ia molecules and
upregulation of HLA-E could mean that HLA-E-restricted
CTLs might play a major role in antivirus defenses [37].
Finally, in view of the broad tissue expression of HLA-
E, HLA-E-restricted CTLs should be investigated for their
possible involvement in the rejection of HLA class Ia-
deﬁcient tumors. In this context, it should be stressed that
frequently tumor cells may fail to express one or more HLA
class Ia alleles or may display a general downregulation of
HLA class Ia surface expression. Both these circumstances,
might allow the induction of HLA-E-restricted CD8+ T-cell
responses against cancer-associated antigens. Along this line,
the increased expression of HLA-E in diﬀerent tumors and
the recent demonstration in mice that the nonclassical Qa-
1b molecule (i.e., the murine HLA-E homologue) plays a
prominent role as a restriction element for CD8+ Tc e l l si n
the adaptive immune response to TAP-deﬁcient tumors [57],
strongly suggest the need of intensive investigation in this
ﬁeld.
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